Loading company details...
Beta
Latest Form 4 (Oct 5, 2026): Epperly Melissa B, (Director): Exercise/Conversion of 17,750 shares, $79.2K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 5, 2026 | Epperly Melissa B, | Exercise/Conversion | 17,750 | $79.2K |
| Oct 3, 2026 | Matthew Gline, CEO | Tax Withholding | 76,171 | $2.79M |
| Oct 3, 2026 | Frank Torti, President and Vant Chair | Tax Withholding | 40,309 | $1.47M |
| Oct 2, 2026 | Mayukh Sukhatme, President & CIO | Tax Withholding | 46,879 | $1.71M |
| Oct 2, 2026 | Eric Venker, President & Immunovant CEO | Exercise/Conversion | 200,000 | $770.0K |
| Sep 23, 2026 | Jennifer Humes, Chief Accounting Officer | Tax Withholding | 3,880 | $154.3K |
| Sep 22, 2026 | Richard Pulik, CFO | Tax Withholding | 2,129 | $84.7K |
| Sep 19, 2026 | Keith S. Manchester | Grant/Award | 5,054 | n/a |
| Sep 18, 2026 | Daniel Allen Gold | Grant/Award | 5,054 | n/a |
| Sep 18, 2026 | Ilan Oren | Grant/Award | 5,054 | n/a |